APPENDIX TO PRESS RELEASE 11 MARCH 2010

Fornix BioSciences N.V.

CONSOLIDATED INCOME STATEMENT

for the financial year from 1 January 2009 to 31 December 2009
with comparative figures for the 2008 financial year

	2009	**2008**
Income	37,756	39,826
Cost of sales	7,312	6,951
Gross result	**30,444**	**32,875**
Other Income	**266**	**216**
Distribution costs	1,464	1,561
Personnel costs	7,378	8,130
Travel expenses	1,293	1,333
Depreciation and amortisation	572	471
Accommodation costs	309	308
Research and development costs	3,419	5,830
Quality control costs	220	342
Production and warehouse costs	130	142
General overheads	3,274	3,765
Charged on to production and trading inventories	(1,250)	(1,425)
Sum of the costs	**16,809**	**20,457**
Result from operating activities	**13,901**	**12,634**
Net financing income/expenses	906	1,296
Profit before taxation	**14,807**	**13,930**
Tax on profits	3,758	3,665
Profit for the financial year	**11,049**	**10,265**
Attributable to:		
Shareholders of the parent company	11,049	10,265
Minority interest	-	-
Profit for the financial year	**11,049**	**10,265**
Ordinary earnings per share (in €)	1.43	1.39
Diluted earnings per share (in €)	1.43	1.39

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the financial year from 1 January 2009 to 31 December 2009
with comparative figures for the 2008 financial year

	2009	2008
Profit for the financial year	**11,049**	**10,265**
Other comprehensive income:		
Exercise of staff options	-	476
Income tax on other comprehensive income	-	-
Other comprehensive income for the financial year, net of income tax	**-**	**476**
Total comprehensive income for the financial year	**11,049**	**10,741**
Attributable to:		
Shareholders of the parent company	11,049	10,741
Minority interest	-	-
Total comprehensive income for the financial year	**11,049**	**10,741**

CONSOLIDATED BALANCE SHEET

(before allocation of the result)
at 31 December 2009 with comparative figures as at 31 December 2008

	31 December 2009	31 December 2008
ASSETS		
Non-current assets		
Intangible assets	13,307	13,750
Property, plant and equipment	3,135	3,054
Deferred tax assets	91	80
Total Non-current assets	**16,533**	**16,884**
Current assets		
Inventories	4,294	3,746
Trade and other receivables	5,206	7,747
Cash and cash equivalents	35,158	32,021
Total Current assets	**44,658**	**43,514**
Total Assets	**61,191**	**60,398**
EQUITY AND LIABILITIES		
Shareholders' equity		
Paid-up and called-up share capital	1,208	1,157
Share premium	35,053	32,896
Other reserves	7,499	7,594
Profit for the financial year	11,049	10,265
Total Shareholders' equity attributable to shareholders of the parent company	**54,809**	**51,912**
Minority interest	1	1
Total Shareholders' equity	**54,810**	**51,913**
Non-current liabilities		
Employee benefits	40	38
Deferred tax liabilities	254	259
Total Non-current liabilities	**294**	**297**
Current liabilities		
Trade payables	1,316	2,571
Taxes payable	646	308
Other items to be paid	4,125	5,309
Total Current liabilities	**6,087**	**8,188**
Total Equity and liabilities	**61,191**	**60,398**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Paid-up and called-up share capital	Share premium	Shares in treasury	Retained earnings	Total other reserves	Profit for the financial year	Total
Balance at 1 January 2008	**1,089**	**27,016**	**(2,496)**	**9,617**	**7,121**	**13,981**	**49,207**
Total comprehensive income for the financial year							
Profit for 2008 financial year	-	-	-	-	-	10,265	10,265
Appropriation of 2007 result	-	-	-	4,652	4,652	(4,652)	-
Exercise of personnel options	6	470	-	-	-	-	476
Total comprehensive income for the financial year	**6**	**470**	**-**	**4,652**	**4,652**	**5,613**	**10,741**
Transactions with shareholders in equity							
Dividend payment 2007	37	4,270	-	-	-	(9,329)	(5,022)
Interim dividend 2008	23	1,140	-	(4,666)	(4,666)	-	(3,503)
Issue of shares in the context of the share ownership plan	2	-	-	-	-	-	2
Cost of share ownership plan 2008	-	-	-	487	487	-	487
Total transactions with shareholders	**62**	**5,410**	**-**	**(4,179)**	**(4,179)**	**(9,329)**	**(8,036)**
Balance at 31 December 2008	**1,157**	**32,896**	**(2,496)**	**10,090**	**7,594**	**10,265**	**51,912**
Total comprehensive income for the financial year							
Profit for 2009 financial year	-	-	-	-	-	11,049	11,049
Appropriation of 2008 result	-	-	-	4,818	4,818	(4,818)	-
Total comprehensive income for the financial year	**-**	**-**	**-**	**4,818**	**4,818**	**6,231**	**11,049**
Transactions with shareholders in equity							
Dividend payment 2008	22	854	-	-	-	(5,447)	(4,571)
Interim dividend 2009	26	1,303	-	(4,866)	(4,866)	-	(3,537)
Issue of shares in the context of the share ownership plan	3	-	-	-	-	-	3
Cost of share ownership plan 2009	-	-	-	(47)	(47)	-	(47)
Total transactions with shareholders	**51**	**2,157**	**-**	**(4,913)**	**(4,913)**	**(5,447)**	**(8,152)**
Balance at 31 December 2009	**1,208**	**35,053**	**(2,496)**	**9,995**	**7,499**	**11,049**	**54,809**

CONSOLIDATED CASH FLOW STATEMENT

for the financial year from 1 January 2009 to 31 December 2009
with comparative figures for the 2008 financial year

	2009		2008	
Cash flow from operating activities				
Receipts from customers	40,920		41,570	
Payments to suppliers and employees	(27,948)		(29,118)	
Net cash flow from business operations		12,972		12,452
Interest received	1,906		726	
Interest paid	(6)		(3)	
Tax paid on profits	(3,226)		(3,355)	
Grants received	176		15	
Cash flow from other operating activities		(1,150)		(2,617)
Net cash flow from operating activities		**11,822**		**9,835**
Cash flow from investing activities				
Acquisition of subsidiaries	-		(1,299)	
Acquisition activities DeCube® products	-		(1250)	
Investments in intangible assets	(10)		(32)	
Investments in property, plant and equipment	(569)		(422)	
Divestment in subsidiaries	2		-	
Net cash flow from investing activities		**(577)**		**(3,003)**
Cash flow from financing activities				
Earnings from exercise of staff options	-		476	
Dividend paid	(8,108)		(8,525)	
Net cash flow from financing activities		**(8,108)**		**(8,049)**
Net increase/decrease in cash and cash equivalents		**3,137**		**(1,217)**
Cash and cash equivalents at 1 January		32,021		33,235
Cash acquired subsidiaries		-		3
Cash and cash equivalents at 31 December		**35,158**		**32,021**

Notes

1 General
The financial data as reported in this appendix to the press release are derived from the yet undetermined annual accounts of Fornix BioSciences N.V. (the ‘Company’) but do not represent the full annual accounts. The Company’s consolidated annual accounts for 2009 include the Company and its subsidiaries (together referred to as the “Group”).

The annual report and annual accounts were discussed in the supervisory Board meeting of 8 March 2010 and will be submitted to the Annual General Meeting of shareholders for adoption on 23 April 2010. The auditors of Fornix BioSciences N.V. have issued an unqualified opinion on these annual accounts.

Publication of the full annual accounts 2009 will be available at the latest on 26 March 2010.

The annual accounts are not yet filed at The Dutch Trade Register.

2 Statement of compliance
The annual accounts 2009 have been prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union and with Part 9 of Book 2 of the Netherlands Civil Code.

3 Basis of preparation
The consolidated annual accounts are presented in thousands of euros.
The Group reports according to IFRS. For the year 2009 no important changes occurred with regard to the accounting principles of the Group.

4 Use of estimates and judgements
The preparation of the annual accounts requires the management of the Company to form opinions and to make estimates and assumptions that influence the application of policies and the reported values of assets and liabilities and of income and expenses. The actual outcomes may differ from these estimates.